|
"...quite remarkable... 1 year experiment of age reversing with epigenetics..."
|
1
|
Resverlogix Corp.
|
Feb 03, 2023 10:42AM
|
|
Re: Long term risks associated with covid
|
1
|
Resverlogix Corp.
|
Jan 06, 2022 10:03AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
1
|
Resverlogix Corp.
|
Nov 29, 2021 07:52PM
|
|
Re: Response
|
2
|
Resverlogix Corp.
|
Jan 23, 2024 12:59PM
|
|
Re: Long Covid
|
2
|
Resverlogix Corp.
|
Jan 22, 2024 06:07PM
|
|
Re: Time keeps ticking
|
3
|
Resverlogix Corp.
|
Nov 19, 2021 01:24PM
|
|
Re: Ethics
|
3
|
Resverlogix Corp.
|
May 13, 2021 09:44PM
|
|
Re: RVX's place in therapy - future prediction
|
3
|
Resverlogix Corp.
|
Mar 15, 2021 09:10AM
|
|
Re: Resverlogix: The Future of Drug Development, CEO Clip Video
|
3
|
Resverlogix Corp.
|
Dec 16, 2021 06:25PM
|
|
Epigenetics and Aging: The effects of DNA breakage and repair
|
3
|
Resverlogix Corp.
|
Jan 28, 2023 09:44PM
|
|
Re: A look at the competition.
|
3
|
Resverlogix Corp.
|
May 17, 2021 09:28PM
|
|
Re: Give us just one or two NR’s - money, partners & timeframe
|
4
|
Resverlogix Corp.
|
Apr 13, 2021 02:19PM
|
|
Re: Here is the example of the danger of the COVID trial to RVX...
|
5
|
Resverlogix Corp.
|
Nov 11, 2021 01:22PM
|
|
Re: Study results?
|
5
|
Resverlogix Corp.
|
Mar 07, 2022 11:56AM
|
|
Re: The BET Protein Inhibitor Apabetalone Rescues Diabetes-induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1
|
5
|
Resverlogix Corp.
|
Dec 21, 2021 08:42PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
5
|
Resverlogix Corp.
|
Apr 05, 2022 06:13PM
|
|
Re: RVX's place in therapy - future prediction
|
5
|
Resverlogix Corp.
|
Mar 13, 2021 03:50PM
|
|
Re: Long Covid
|
5
|
Resverlogix Corp.
|
Jan 22, 2024 10:37AM
|
|
Re: Long Covid
|
5
|
Resverlogix Corp.
|
Jan 22, 2024 03:40PM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
6
|
Resverlogix Corp.
|
Nov 29, 2021 07:45PM
|
